Literature DB >> 11759998

Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996-2000).

M Cohen1, J C Wright, W R Brawner, A N Smith, R Henderson, E N Behrend.   

Abstract

OBJECTIVE: To evaluate responses of cats with vaccine-associated sarcomas to treatment with surgery and radiotherapy, with or without adjunctive chemotherapy.
DESIGN: Retrospective study. ANIMALS: 76 cats (78 tumors). PROCEDURE: Medical records were reviewed. Factors potentially associated with survival time, time to recurrence, and time to development of metastases were evaluated.
RESULTS: Following excision, electron beam radiation, and, in some cases, chemotherapy, 32 (41%) cats experienced recurrence, and 9 (12%) cats developed metastases. One- and 2-year survival rates were 86 and 44%, respectively. Median survival time from onset of disease was 730 days (range, 30 to 2,014 days). Median disease-free interval was 405 days (range, 30 to 925 days). Cats that underwent only 1 surgery prior to radiotherapy had a lower recurrence rate than did cats that underwent > 1 surgery and had a significantly longer disease-free interval. Survival time and disease-free interval decreased as time between surgery and the start of radiotherapy increased. Cats that developed metastases had significantly shorter survival times and disease-free intervals than did cats that did not develop metastases. Castrated male cats had a significantly shorter survival time than did spayed female cats. Cats with larger tumors prior to the first surgery had shorter survival times. Twenty-six cats received chemotherapy in addition to surgery and radiotherapy. Whether cats received chemotherapy was not associated with recurrence rate, metastasis rate, or survival time. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that excision followed by electron beam irradiation may be beneficial for treatment of cats with vaccine-associated sarcomas. Extent of excision prior to radiotherapy did not seem to be associated with recurrence rate.

Entities:  

Mesh:

Year:  2001        PMID: 11759998     DOI: 10.2460/javma.2001.219.1582

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  8 in total

1.  Pelvic Endoprosthesis after Hemipelvectomy Using a 3D-Printed Osteotomy Guide for Infiltrative Osteoma in a Cat.

Authors:  Yoonho Roh; Jaemin Jeong; Youngjin Jeon; Daehyun Kim; Seongmok Jeong; Haebeom Lee
Journal:  Vet Sci       Date:  2022-05-16

2.  Temporal changes in characteristics of injection-site sarcomas in cats: 392 cases (1990-2006).

Authors:  Stephen C Shaw; Michael S Kent; Ira K Gordon; Cameron J Collins; Tamara A Greasby; Laurel A Beckett; Genevieve M Hammond; Katherine A Skorupski
Journal:  J Am Vet Med Assoc       Date:  2009-02-01       Impact factor: 1.936

3.  Photodynamic hyperthermal chemotherapy with indocyanine green in feline vaccine-associated sarcoma.

Authors:  Masaki Onoyama; Takeshi Tsuka; Tomohiro Imagawa; Tomohiro Osaki; Akihiko Sugiyama; Kazuo Azuma; Norihiko Ito; Kazuhiko Kawashima; Yoshiharu Okamoto
Journal:  Oncol Lett       Date:  2015-08-03       Impact factor: 2.967

Review 4.  Current knowledge on feline injection-site sarcoma treatment.

Authors:  Katarzyna Zabielska-Koczywąs; Anna Wojtalewicz; Roman Lechowski
Journal:  Acta Vet Scand       Date:  2017-07-17       Impact factor: 1.695

Review 5.  Vaccine-associated feline sarcoma: current perspectives.

Authors:  Corey F Saba
Journal:  Vet Med (Auckl)       Date:  2017-01-12

6.  Biological indicators of chemoresistance: an ex vivo analysis of γH2AX and p53 expression in feline injection-site sarcomas.

Authors:  Yike Bing; Zacharie Wund; Tina Abratte; Lucia Borlle; Susie Kang; Teresa Southard; Kelly R Hume
Journal:  Cancer Cell Int       Date:  2018-11-22       Impact factor: 5.722

7.  Origins of injection-site sarcomas in cats: the possible role of chronic inflammation-a review.

Authors:  Kevin N Woodward
Journal:  ISRN Vet Sci       Date:  2011-04-12

8.  Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega.

Authors:  Verena Hampel; Bianca Schwarz; Christine Kempf; Roberto Köstlin; Ulrike Schillinger; Helmut Küchenhoff; Nora Fenske; Thomas Brill; Johannes Hirschberger
Journal:  J Vet Intern Med       Date:  2007 Nov-Dec       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.